Apimeds Pharmaceuticals US, Inc.

APUS · NYSE MKT · Healthcare / Drug Manufacturers - Specialty & Generic

2.23USD-0.04 (-1.76%)

Price History

Full chart

Market Stats

Previous Close2.27

Open2.50

Day Range2.18 – 2.50

52-Week Range1.51 – 40.31

Volume31.00K

Market Cap7.42M

P/E (TTM)0.00

Forward P/E0.00

EPS-77.30

Dividend Yield0.00%

50-Day Avg4.17

200-Day Avg12.70

About

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Vinod Menon
Employees2
Headquarters100 Matawan Rd, Matawan, NJ, United States, 07747, USA
Websitehttps://www.mindwavedao.com

Leadership

Mr. Erik C. EmersonPresident · b. 1971
Mr. Erick J. FrimChief Financial Officer · b. 1958
Dr. Vinod MenonFounder & Co-CEO · b. 1978
Captain Sandeep Singh YadavChief Operating Officer
Mr. Amardeep SinghChief Technology Officer

Financials

Income Statement

Currency: USD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0	0
Cost of Revenue	-	-	-	-	5.71K
Gross Profit	-	-	-	-	-5.71K
Operating Expense	-	-	-	-	11.91M
Operating Income	-1.02M	-639.53K	-747.44K	-1.28M	-11.91M
EBITDA	-1.02M	-639.53K	-739.63K	-1.27M	-5.71M
Net Income	-1.03M	-668.67K	-777.69K	-1.39M	-6.00M
R&D	489.94K	368.00K	98.54K	0	1.63M
Interest Expense	6.74K	29.14K	38.07K	117.72K	283.01K

Balance Sheet

Currency: USD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	172.17K	6.17K	422.08K	13.06K	164.18M
Total Liabilities	410.65K	719.78K	390.20K	1.37M	10.84M
Total Equity	-238.48K	-713.61K	31.87K	-1.36M	153.35M
Cash	171.44K	6.17K	410.48K	3.46K	1.64M
Total Debt	400.00K	660.00K	266.89K	596.84K	7.76M
Net Debt	228.56K	653.83K	-143.59K	593.39K	6.12M

Cash Flow

Currency: USD	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-823.11K	-448.17K	-627.79K	-733.53K	-8.93M
Investing Cash Flow	-	-	-	-	-10.06M
Financing Cash Flow	400.00K	282.90K	1.03M	326.50K	20.62M
Capital Expenditure	0	0	0	0	57.33K
Free Cash Flow	-823.11K	-448.17K	-627.79K	-733.53K	-8.98M
FCF to OCF	100.00%	100.00%	100.00%	100.00%	100.64%

Earnings

Report Date	May 19, 2025	Aug 19, 2025	Nov 12, 2025	Dec 31, 2025	Mar 31, 2026	Aug 14, 2026	Nov 11, 2026
EPS Estimate	0.00	-	-	-	-	-	-
EPS Actual	-0.05	-0.26	-0.14	-0.92	-22.60	-11.77	-
Surprise	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap7.42M

Enterprise Value17.75M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book0.03

EPS-77.30

Book Value0.649

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity0.00%

Return on Assets-409.38%

Shares Outstanding1.51M

Shares Float2.05M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Jul 24, 20261:10